With innovative, solution-oriented, and sustainable developments, the Gerresheimer team presents itself at Pharmapack and looks forward to visits from the trade public. In the presentation "Services beyond product" Gerresheimer presents new products and services.
The compatibility of innovation, solution and sustainability are at the top of Gerresheimer's agenda. The company also demonstrates this at Pharmapack with its new developments for primary packaging, drug delivery systems and medical and diagnostic products. In addition, Gerresheimer focusses on the development of packaging and delivery solutions for newly developed biologics.
Pharmapack takes place on February 1 and 2 in Paris at the Paris Expo, Porte de Versailles. The Gerresheimer team is expecting its visitors in Hall 7.2 at Stand B60/B64. Here are some product highlights:
Improving quality while reducing TCO
Dr. Wenzel Novak PhD, Senior Global Director Business Development MDS will present the new EZ-Fill Smart Platform for Vials. It offers a powerful route improving pharmaceutical manufacturing quality standard while reducing the Total Cost of Ownership (TCO). The presentation will be held from 10.50 - 11.20 on February 1st Paris Expo, Porte de Versailles - Hall 7.2.
Gx RTF Vials - The solution for clinical trials and industrialisation
The vials are depyrogenated, sterile and ready-to-use for injectables of highest quality and flexibel through different packaging configurations including SG EZ-fill packaging format. They are produced according to cGMP, washed in a cleanroom, packed in tray or nest and tub and sterilised, ready to fill. They are also available as elite glass vials.
Due to the ready to fill status, the customer can proceed without the following steps: no need for washing and sterilisation. This means no need to invest in machinery and manpower. Due to many years of experience in the area of prefillable primary packaging, Gerresheimer can minimise risks for the customers which could occur with sterile packaging.
The Gx RTF injection vials are made of borosilicate glass type I and meet all common requirements of the applicable ISO standards and pharmacopoeias (USP and Ph. Eur.).
Gx InnoSafe protects against unintentional needlestick injuries and is easy to fill
Nurses are among the occupational groups with the most frequent cuts and puncture wounds. This can lead to infection with dangerous pathogens such as hepatitis B and C viruses or HIV. The Gx InnoSafe safety syringe is the first syringe on the market with a passive needle protection system. Its function prevents anyone from accidentally injuring themselves through an unintentional needle stick on a syringe that has already been used, as the needle is fixed in a sleeve after use. In addition to these unique safety features, a special feature of the Gx InnoSafe syringe is that it can be processed on all existing filling lines without any additional preparation or conversion steps. Furthermore, it complies with all regulations without any additional investment.
With DropControl, Gerresheimer has developed a new dropper insert for modern drugs with low viscosity for ophthalmology, which prevents the drug from flowing out uncontrollably during use.
DropControl for new ophthalmic formulations
With DropControl, Gerresheimer has developed a new dropper insert for modern drugs with low viscosity for ophthalmology, which prevents the drug from flowing out uncontrollably during use. The new generation of eye drop solutions have modified properties compared to the former water-based eye-drop solutions to improve the efficiency and the pharmaceutical effectiveness. For such eye-drop formulations the function of a conventional eyedropper require a modification to prevent uncontrolled dropping when the patient turns the eyedropper to release the droplets.
Product information at the stand for sustainable download
Gerresheimer is serious about sustainability and this year for the first time will offer its information at the stand for direct download via URL codes instead of printed catalogs and brochures.
